7.5 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | intake_tier | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | GLP-1 Managed-Access Operating Systems: How Payers Are Building Infrastructure Beyond Formulary | on/healthcare tech (strategy analysis) | https://www.onhealthcare.tech/p/how-commercial-insurers-self-insured | 2026-01-01 | health | analysis | unprocessed | high |
|
research-task |
Content
Strategic analysis of how payers, PBMs, and employers are restructuring GLP-1 access as a managed-access operating system rather than a standard formulary decision.
The core argument: Traditional yes/no formulary structure cannot accommodate GLP-1 economics:
- Eligible population: 36.2 million commercially insured adults
- Cost: $1,000-$1,200+/month recurring
- Multiple indications: obesity, T2D, cardiovascular risk (2024), MASH F2-F3 fibrosis (2025), sleep apnea (December 2024)
- The decision tree: which populations qualify, under what thresholds, through which channels, with what behavioral gates, at what subsidy levels, with what discontinuation rules
This requires an operating system, not a formulary.
Payer infrastructure being built (2025-2026):
Evernorth EncircleRx:
- Manages 9 million enrolled lives
- 15% cost cap or 3:1 savings guarantee
- ~$200 million saved since 2024
- $200 copay cap on Wegovy and Zepbound added 2025
Optum Rx Weight Engage:
- Pairs GLP-1 access with obesity specialist navigation, coaching, lifestyle programs
UHC Total Weight Support:
- Requires coaching engagement (Real Appeal Rx or WeightWatchers) as COVERAGE PREREQUISITE
- [Note: WeightWatchers bankruptcy creates a gap here — the mandated vendor went bankrupt]
Manufacturer direct-to-employer channels (early 2026):
Eli Lilly Employer Connect (March 5, 2026):
- $449/dose Zepbound direct to employers (vs. $1,000+ retail)
- 15+ program administrator partnerships: GoodRx, Teladoc, Calibrate, Form Health, Waltz
- Bypasses PBMs entirely
Novo Nordisk parallel DTE:
- Waltz Health and 9amHealth partnerships
- Launched January 1, 2026
Indication expansion creating complexity:
- Wegovy: cardiovascular risk reduction (2024)
- Wegovy: noncirrhotic MASH with F2-F3 fibrosis (2025)
- Zepbound: moderate-to-severe obstructive sleep apnea (December 2024) Each indication requires distinct medical-necessity criteria and cost-offset narratives.
The persistence problem (framing the infrastructure need): Meta-regression data:
- ~50% discontinuation within one year
- ~60% weight regain within 12 months of cessation
- 1-in-12 patients remain on therapy at three years (Prime Therapeutics, cited by Mercer) These numbers make the ROI case for managed access infrastructure: without behavioral gates, drug-only GLP-1 coverage is cost without durable benefit.
Infrastructure opportunities identified:
- Utilization management infrastructure
- Outcomes-based contracting frameworks
- Indication-specific cardiometabolic programs
- Adherence, tapering, and discontinuation management systems
- Employer-side financing or subsidy products
Coverage expansion from search data:
- 43% of 5,000+ employee firms cover GLP-1s for weight loss (up from 28% in 2024)
- 34% now require behavioral participation as coverage condition (up from 10%)
- State mandates emerging: North Dakota first (January 2025), California/Connecticut/West Virginia introducing similar legislation
- CMS: Medicare Part D coverage beginning January 2027
Agent Notes
Why this matters: The "managed-access operating system" framing is conceptually important. The previous KB description of GLP-1 economics treated the drug as a standalone product with an adherence problem. This analysis shows that payers are treating the drug + behavioral infrastructure as a SYSTEM — a complex managed product requiring ongoing operational management. This changes the nature of what business opportunities exist.
What surprised me: The manufacturer direct-to-employer channels (Lilly Employer Connect, Novo/Waltz/9amHealth) launched in early 2026. This is manufacturers BYPASSING PBMs to sell directly to employers. If successful, this represents a structural shift in who controls GLP-1 access architecture. The PBMs (Evernorth, Optum Rx) are building infrastructure to stay relevant; manufacturers are trying to go around them.
What I expected but didn't find: More detail on which employers are using which vendor. UHC requires Real Appeal Rx or WeightWatchers coaching — but WeightWatchers went bankrupt in May 2025 (three months before this analysis). Does UHC now require the post-bankruptcy "clinical-behavioral hybrid" WeightWatchers? This gap in the record is interesting.
New structural insight — the infrastructure layer is separate from the coaching layer: The previous session identified "behavioral support" as the moat opportunity. This analysis reveals a more complex infrastructure stack:
- Access layer: PBM formulary, prior auth, utilization management (Evernorth, Optum Rx)
- Behavioral coaching layer: Omada, Noom, Calibrate, WeightWatchers — where atoms-to-bits moat applies
- Contracting layer: Outcomes-based contracts, risk-sharing (Evernorth's cost cap)
- Manufacturer direct layer: Lilly Employer Connect, Novo/Waltz — bypassing traditional channels
Each layer has different moat characteristics. The behavioral coaching layer is where atoms-to-bits applies. The access/contracting layer is where PBM scale applies. The manufacturer direct layer is where brand power applies.
KB connections:
- four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable — the managed-access OS is a new configuration that doesn't fit cleanly into the existing four-model framework
- value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk — behavioral gates are a new mechanism for risk alignment at the pharmacy benefit level
Extraction hints:
- CLAIM: "GLP-1 economics require managed-access operating systems beyond standard formulary — payers are building multi-layer access infrastructure covering eligibility, behavioral gates, indication-specific criteria, and discontinuation management" — confidence: likely
- CLAIM: "Manufacturer direct-to-employer channels (Lilly Employer Connect March 2026, Novo Nordisk January 2026) represent structural challenge to PBM intermediation in GLP-1 access" — confidence: experimental (too new to confirm durability)
- UPDATE: The "inflationary through 2035" GLP-1 claim is further complicated by manufacturer DTE channels at $449/dose vs. $1,000 retail — pricing compression may be faster than expected
Context: on/healthcare.tech is a B2B healthcare strategy newsletter (paywalled). This represents sophisticated market analysis from the payer/employer strategy perspective, not consumer-facing.
Curator Notes
PRIMARY CONNECTION: value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk WHY ARCHIVED: The "managed-access OS" framing is conceptually new — it positions GLP-1 payer infrastructure as a distinct platform opportunity from behavioral coaching, adding a layer to the claim landscape EXTRACTION HINT: Extract the managed-access OS framing as a new claim; separately extract the manufacturer-DTE structural disruption as a second claim — these are two distinct insights from the same source